ZVRA Quote, Financials, Valuation and Earnings

ADMA Biologics, Inc. has a net margin of -2.09% compared to Zevra Therapeutics, Inc.'s net margin of 27.14%. Zevra Therapeutics, Inc.'s return on equity of 44.06% beat ADMA Biologics, Inc.'s return on equity of 58.71%.

Zevra Therapeutics, Inc. has a consensus price target of $22.54, signalling upside risk potential of 162.14%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 56.22%. Given that Zevra Therapeutics, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Zevra Therapeutics, Inc. is more attractive than ADMA Biologics, Inc..

Zevra Therapeutics, Inc. has a beta of 0.989, which suggesting that the stock is 1.074% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.502%.

Zevra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.

Zevra Therapeutics, Inc. quarterly revenues are $26.1M, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Zevra Therapeutics, Inc.'s net income of -$544K is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Zevra Therapeutics, Inc.'s price-to-earnings ratio is 13.63x while ADMA Biologics, Inc.'s PE ratio is 19.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics, Inc. is 5.57x versus 8.27x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alnylam Pharmaceuticals, Inc. has a net margin of -2.09% compared to Zevra Therapeutics, Inc.'s net margin of 20.1%. Zevra Therapeutics, Inc.'s return on equity of 44.06% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.

Zevra Therapeutics, Inc. has a consensus price target of $22.54, signalling upside risk potential of 162.14%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $479.79 which suggests that it could grow by 46.21%. Given that Zevra Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Zevra Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

Zevra Therapeutics, Inc. has a beta of 0.989, which suggesting that the stock is 1.074% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.

Zevra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Zevra Therapeutics, Inc. quarterly revenues are $26.1M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Zevra Therapeutics, Inc.'s net income of -$544K is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Zevra Therapeutics, Inc.'s price-to-earnings ratio is 13.63x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,364.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics, Inc. is 5.57x versus 13.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Verastem, Inc. has a net margin of -2.09% compared to Zevra Therapeutics, Inc.'s net margin of -876.34%. Zevra Therapeutics, Inc.'s return on equity of 44.06% beat Verastem, Inc.'s return on equity of -1773.4%.

Zevra Therapeutics, Inc. has a consensus price target of $22.54, signalling upside risk potential of 162.14%. On the other hand Verastem, Inc. has an analysts' consensus of $16.63 which suggests that it could grow by 149.25%. Given that Zevra Therapeutics, Inc. has higher upside potential than Verastem, Inc., analysts believe Zevra Therapeutics, Inc. is more attractive than Verastem, Inc..

Zevra Therapeutics, Inc. has a beta of 0.989, which suggesting that the stock is 1.074% less volatile than S&P 500. In comparison Verastem, Inc. has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.56%.

Zevra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics, Inc. pays -- of its earnings as a dividend. Verastem, Inc. pays out -- of its earnings as a dividend.

Zevra Therapeutics, Inc. quarterly revenues are $26.1M, which are larger than Verastem, Inc. quarterly revenues of $11.2M. Zevra Therapeutics, Inc.'s net income of -$544K is higher than Verastem, Inc.'s net income of -$98.5M. Notably, Zevra Therapeutics, Inc.'s price-to-earnings ratio is 13.63x while Verastem, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics, Inc. is 5.57x versus 31.17x for Verastem, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XOMA Royalty Corp. has a net margin of -2.09% compared to Zevra Therapeutics, Inc.'s net margin of 52.48%. Zevra Therapeutics, Inc.'s return on equity of 44.06% beat XOMA Royalty Corp.'s return on equity of 17.31%.

Zevra Therapeutics, Inc. has a consensus price target of $22.54, signalling upside risk potential of 162.14%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $64.50 which suggests that it could grow by 159.45%. Given that Zevra Therapeutics, Inc. has higher upside potential than XOMA Royalty Corp., analysts believe Zevra Therapeutics, Inc. is more attractive than XOMA Royalty Corp..

Zevra Therapeutics, Inc. has a beta of 0.989, which suggesting that the stock is 1.074% less volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.855, suggesting its less volatile than the S&P 500 by 14.461%.

Zevra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. Zevra Therapeutics, Inc. pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zevra Therapeutics, Inc. quarterly revenues are $26.1M, which are larger than XOMA Royalty Corp. quarterly revenues of $9.4M. Zevra Therapeutics, Inc.'s net income of -$544K is lower than XOMA Royalty Corp.'s net income of $10.3M. Notably, Zevra Therapeutics, Inc.'s price-to-earnings ratio is 13.63x while XOMA Royalty Corp.'s PE ratio is 33.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics, Inc. is 5.57x versus 8.65x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.